Yoshihiko Tasaki

Nagoya, 4678601, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 34 publications

Durable Progression-Free and Treatment-Free Survival After Nivolumab Plus Ipilimumab Therapy in Metastatic Renal Cell Carcinoma: A Real-World Study with a 5-Year Minimum Follow-Up.

Durable Progression-Free and Treatment-Free Survival After Nivolumab Plus Ipilimumab Therapy in Metastatic Renal Cell Carcinoma: A Real-World Study with a 5-Year Minimum Follow-Up.

Journal: Cancers

Published: March 08, 2026

Prognostic Impact of Early GNRI Sustainability in Metastatic Urothelial Carcinoma Receiving Pembrolizumab.

Prognostic Impact of Early GNRI Sustainability in Metastatic Urothelial Carcinoma Receiving Pembrolizumab.

Journal: Anticancer research

Published: January 23, 2026

Eosinophil Proportion May Serve as a Candidate Biomarker for Adverse Events in Patients With Urothelial Carcinoma Treated With Enfortumab Vedotin.

Eosinophil Proportion May Serve as a Candidate Biomarker for Adverse Events in Patients With Urothelial Carcinoma Treated With Enfortumab Vedotin.

Journal: Cancer medicine

Published: January 14, 2026

Integrating pharmacokinetic modeling and wearable-derived physiological data to assess pain intensity in patients with advanced urologic cancer.

Integrating pharmacokinetic modeling and wearable-derived physiological data to assess pain intensity in patients with advanced urologic cancer.

Journal: Japanese journal of clinical oncology

Published: October 28, 2025

Sustained Drug-Drug Interaction Between Cyclosporine and Apalutamide in a Patient With Metastatic Hormone-Sensitive Prostate Cancer: A Case Report and Evaluation of CYP3A4 Induction via Pregnane X Receptor Activation by Apalutamide.

Sustained Drug-Drug Interaction Between Cyclosporine and Apalutamide in a Patient With Metastatic Hormone-Sensitive Prostate Cancer: A Case Report and Evaluation of CYP3A4 Induction via Pregnane X Receptor Activation by Apalutamide.

Journal: Case reports in oncological medicine

Published: October 21, 2025

A high eosinophil proportion increases the risk of skin-related adverse events induced by apalutamide in patients with prostate cancer.

A high eosinophil proportion increases the risk of skin-related adverse events induced by apalutamide in patients with prostate cancer.

Journal: Frontiers in immunology

Published: August 07, 2025

Real-world outcomes of immune checkpoint inhibitor-based combination therapy in older adult patients with metastatic renal cell carcinoma: a multi-center, retrospective analysis.

Real-world outcomes of immune checkpoint inhibitor-based combination therapy in older adult patients with metastatic renal cell carcinoma: a multi-center, retrospective analysis.

Journal: Frontiers in immunology

Published: July 17, 2025

Impact of high relative dose intensity on effectiveness and treatment continuity of IO-TKI therapy in Japanese advanced renal cell carcinoma.

Impact of high relative dose intensity on effectiveness and treatment continuity of IO-TKI therapy in Japanese advanced renal cell carcinoma.

Journal: Scientific reports

Published: July 10, 2025

Evaluation of the Safety of Robot-Assisted Radical Cystectomy for Bladder Cancer in Octogenarians.

Evaluation of the Safety of Robot-Assisted Radical Cystectomy for Bladder Cancer in Octogenarians.

Journal: Asian journal of endoscopic surgery

Published: June 29, 2025

Elevation of Eosinophil Proportion After Pembrolizumab Increases the Risk of Immune-Related Adverse Events in Patients With Bladder Cancer.

Elevation of Eosinophil Proportion After Pembrolizumab Increases the Risk of Immune-Related Adverse Events in Patients With Bladder Cancer.

Journal: Cancer medicine

Published: June 26, 2025

Mental Stress Assessment and Clinical Application of Wearable Devices as Evaluable Outcomes in Robotic Prostatectomy.

Mental Stress Assessment and Clinical Application of Wearable Devices as Evaluable Outcomes in Robotic Prostatectomy.

Journal: Annals of surgical oncology

Published: June 05, 2025

Efficacy and safety of anamorelin in patients with metastatic urothelial carcinoma receiving systemic chemotherapy: a randomized controlled study.

Efficacy and safety of anamorelin in patients with metastatic urothelial carcinoma receiving systemic chemotherapy: a randomized controlled study.

Journal: The oncologist

Published: April 04, 2025

Showing 1-12 of 34

Last Updated: 09/26/2026